Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenströms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden. Watch Dr Meletios Dimopoulos, of the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses this groundbreaking study, which could result in a new standard of care for WM.
Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab
